サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1795154

遅発性ジスキネジア治療薬の世界市場

Tardive Dyskinesia Therapeutics

出版日
ページ情報
英文 240 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.55円
遅発性ジスキネジア治療薬の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 240 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

遅発性ジスキネジア治療薬の世界市場は2030年までに56億米ドルに到達

2024年に43億米ドルと推定される遅発性ジスキネジア治療薬の世界市場は、分析期間2024-2030年にCAGR 4.4%で成長し、2030年には56億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるドイテトラベナジン医薬品は、CAGR 5.0%を記録し、分析期間終了時には33億米ドルに達すると予測されます。バルベナジン医薬品セグメントの成長率は、分析期間中CAGR 3.9%と推定されます。

米国市場は11億米ドルと推定、中国はCAGR4.3%で成長予測

米国の遅発性ジスキネジア治療薬市場は2024年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9億210万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.2%と3.8%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の遅発性ジスキネジア治療薬市場- 主要動向と促進要因まとめ

遅発性ジスキネジア（TD）は、抗精神病薬の長期服用に起因する運動障害であり、専用の治療薬への注目が高まっています。

従来の治療はVMAT2阻害薬に依存しており、臨床的検証の結果、VMAT2阻害薬が標準的な治療薬として登場しました。これらの薬剤は症状のコントロールと服用の利便性を向上させたが、新規治療薬のパイプラインは依然として制約を受けており、次世代治療薬の必要性が強調されています。高所得地域は強固なヘルスケアインフラと抗精神病薬の広範な使用により採用が進んでいるが、新興市場は認知度とアクセスの向上に伴い関心が加速しています。薬理学的治療だけでなく、さまざまな治療法の革新がケアを拡大しています。経口投与が一般的であることに変わりはないが、症状が重篤であったり、管理が不十分であったりする患者に対しては注射剤が勢いを増しています。治療法の成熟に伴い、早期診断、モニタリングツール、行動療法や支持的介入を含む統合的アプローチにも注目が集まっています。

薬物療法以外の治療法はどのように進化しているのか？

脳深部刺激療法や経頭蓋磁気刺激療法などの非薬物療法は、インフラやコストの問題からまだ一般的ではないが、関心を集めています。徐放性製剤や個別化された投与スケジュールの技術的改良により、患者の治療成績は向上しています。その結果、アドヒアランスとQOLが中心的な評価指標になりつつあります。

実世界のデータイニシアチブは長期的な転帰の追跡に役立ち、患者の経験やアドヒアランスに関する洞察を提供しています。これらのデータベースは、治療効果、安全性、経済性について規制機関やヘルスケアプロバイダーに情報を提供し、より微妙な治療アルゴリズムやバリューベースのケア戦略への道を開いています。

遅発性ジスキネジア治療薬市場の成長はいくつかの要因によってもたらされる...

TD治療薬市場の成長は、診断の高度化、治療の多様化、患者の認知度向上に関連するいくつかの要因によって牽引されています。TDの世界の有病率の上昇により、潜在的な患者層が拡大しています。診断の進歩と臨床意識の高まりにより、早期介入が可能になっています。精密医療へのシフトは、非薬理学的選択肢を含む個別化治療アプローチへの関心を促しています。さらに、患者登録と転帰の追跡により、現実世界での意思決定と治療へのアクセスが改善されつつあります。これらの複合的な力によって、より迅速で拡張可能なTD治療の展望が形作られつつあります。

セグメント

薬剤（ドイテトラベナジン製剤、バルベナジン製剤、その他薬剤）;製品（遅発性ジスキネジア固形剤、遅発性ジスキネジア錠剤、遅発性ジスキネジアカプセル、遅発性ジスキネジア液剤、遅発性ジスキネジア注射剤）;販売チャネル（病院薬局、ドラッグストア・小売薬局、オンライン販売チャネル、その他販売チャネル）

調査対象企業の例

  • AbbVie Inc.
  • Adamas Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Biogen Inc.
  • Chromium Therapeutics（add pipeline）*
  • Contera Pharma
  • Dr. Reddy's Laboratories
  • Johnson & Johnson
  • Lundbeck A/S
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanis
  • SOM Biotech
  • SteriMax Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP38172

Global Tardive Dyskinesia Therapeutics Market to Reach US$5.6 Billion by 2030

The global market for Tardive Dyskinesia Therapeutics estimated at US$4.3 Billion in the year 2024, is expected to reach US$5.6 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Deutetrabenazine Drug, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Valbenazine Drug segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 4.3% CAGR

The Tardive Dyskinesia Therapeutics market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$902.1 Million by the year 2030 trailing a CAGR of 4.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Tardive Dyskinesia Therapeutics Market - Key Trends & Drivers Summarized

Tardive dyskinesia (TD), a movement disorder stemming from prolonged antipsychotic use, has catalyzed a growing focus on dedicated therapeutics.

Traditional management relied heavily on VMAT2 inhibitors, which have emerged as standard treatments following clinical validation. While these drugs improved symptom control and dosing convenience, the pipeline for novel therapies remains constrained, emphasizing the need for next-gen interventions. High-income regions lead adoption due to robust healthcare infrastructure and widespread antipsychotic use, while emerging markets are showing accelerated interest as awareness and access improve. Beyond pharmacological treatment, a range of delivery innovations is expanding care. Oral administration remains common, but injectables are gaining momentum for patients with severe or poorly managed symptoms. As therapies mature, attention is also turning toward early diagnosis, monitoring tools, and integrative approaches that include behavioral and supportive interventions.

How Are Treatment Modalities Evolving Beyond Medication?

Non-drug interventions such as deep brain stimulation and transcranial magnetic stimulation are gaining interest, though they remain less common due to infrastructure and cost. Technological improvements in extended-release drug formulations and individualized dosing schedules are enhancing patient outcomes. As a result, adherence and quality of life are becoming central performance metrics.

Real-world data initiatives are helping track long-term outcomes, offering insights into patient experience and adherence. These databases inform regulatory bodies and healthcare providers on therapeutic effectiveness, safety, and economic viability, paving the way for more nuanced treatment algorithms and value-based care strategies.

The Growth in the Tardive Dyskinesia Therapeutics Market Is Driven by Several Factors…

The growth in the TD therapeutics market is driven by several factors related to diagnostic sophistication, treatment diversification, and increasing patient recognition. Rising global prevalence of TD is expanding the potential patient base. Advancements in diagnostics and heightened clinical awareness are enabling earlier intervention. The shift toward precision medicine is prompting interest in personalized treatment approaches, including non-pharmacologic options. Additionally, patient registries and outcome tracking are improving real-world decision-making and access to care. These combined forces are shaping a more responsive and scalable TD therapeutic landscape.

SCOPE OF STUDY:

The report analyzes the Tardive Dyskinesia Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Deutetrabenazine Drug, Valbenazine Drug, Other Drugs); Product (Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form, Tardive Dyskinesia Injection); Distribution Channel (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Adamas Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Biogen Inc.
  • Chromium Therapeutics (add pipeline)*
  • Contera Pharma
  • Dr. Reddy's Laboratories
  • Johnson & Johnson
  • Lundbeck A/S
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanis
  • SOM Biotech
  • SteriMax Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Tardive Dyskinesia Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis Rates of Tardive Dyskinesia Due to Improved Clinical Awareness Drive Therapeutic Demand
    • Increased Use of Antipsychotics and Dopamine Receptor Blockers Spurs Incidence of TD
    • Development of VMAT2 Inhibitors Propels Market for Targeted Tardive Dyskinesia Treatments
    • Expansion of Mental Health Services Enhances Access to Early Intervention and Diagnosis
    • Clinical Evidence Supporting Long-Term Efficacy of New Drug Classes Strengthens Physician Adoption
    • Shift Toward Neurologist-Led Management Models Promotes Use of Specialized Therapies
    • Growing Demand for Patient-Centric and Side Effect-Minimized Regimens Supports Treatment Customization
    • FDA Approvals and Label Expansions Fuel Uptake of Novel Small Molecule Therapies
    • Rise in Co-Occurrence With Other Psychiatric Disorders Increases Demand for Combination Therapies
    • Inclusion of TD Therapies in Psychiatric Formularies Boosts Institutional Access
    • Development of Long-Acting Formulations Improves Adherence and Quality of Life Outcomes
    • Monitoring Protocols and Tolerability Data Collection Shape Prescribing Trends in Community Practices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tardive Dyskinesia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tardive Dyskinesia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Tardive Dyskinesia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Deutetrabenazine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Deutetrabenazine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Deutetrabenazine Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Valbenazine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Valbenazine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Valbenazine Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Solid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Tardive Dyskinesia Solid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Tardive Dyskinesia Solid Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Tardive Dyskinesia Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Tardive Dyskinesia Tablets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Tardive Dyskinesia Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Tardive Dyskinesia Capsules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Liquid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Tardive Dyskinesia Liquid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Tardive Dyskinesia Liquid Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Tardive Dyskinesia Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Tardive Dyskinesia Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Tardive Dyskinesia Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • JAPAN
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • CHINA
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • EUROPE
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Tardive Dyskinesia Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • FRANCE
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • GERMANY
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Tardive Dyskinesia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Tardive Dyskinesia Therapeutics by Drug - Deutetrabenazine Drug, Valbenazine Drug and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of World 16-Year Perspective for Tardive Dyskinesia Therapeutics by Drug - Percentage Breakdown of Value Sales for Deutetrabenazine Drug, Valbenazine Drug and Other Drugs for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Tardive Dyskinesia Therapeutics by Distribution Channel - Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of World 16-Year Perspective for Tardive Dyskinesia Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Drug Stores & Retail Pharmacies, Online Distribution Channel, Other Distribution Channels and Hospitals Pharmacies for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for Tardive Dyskinesia Therapeutics by Product - Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of World 16-Year Perspective for Tardive Dyskinesia Therapeutics by Product - Percentage Breakdown of Value Sales for Tardive Dyskinesia Solid Dosage Form, Tardive Dyskinesia Tablets, Tardive Dyskinesia Capsules, Tardive Dyskinesia Liquid Dosage Form and Tardive Dyskinesia Injection for the Years 2014, 2025 & 2030

IV. COMPETITION